This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Decide which cash back credit card you should get by assessing your spending habits. Find the best rewards for you.
27,595 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
AXIA Energia completes its transition to 100% renewable power after divesting coal, delivering robust cash flow and e...
With a $475,000 mortgage and $175,000 in cash from a home sale, the big question is whether to pay down debt or inves...
Warren Buffett's decades-long investing journey shows that patience and a focus on quality beat flashier moves. This ...
Retirees are rethinking a longtime rule of thumb: pay off the mortgage before retirement. With rates higher and marke...
As AI workloads demand more network performance, Arista Networks and Broadcom stand out. This guide breaks down their...
Investors are watching Bullish (BLSH) as Q1 2026 results set the tone for the year. This guide breaks down the earnin...
Opendoor's CEO recently bought 100,000 shares, signaling confidence to shareholders. This article breaks down what t...
A broad market ETF like SCHX hides a sharp concentration at the top. The three largest positions drive about 48% of t...
When a company's CFO makes a notable stock purchase, investors pay attention. This article breaks down what nomad foo...
An accessible analysis of what this $405,000 bj's insider sale means for investors, plus practical steps to read insi...
A high-profile insider sale at PTC Therapeutics coincides with a milestone for product revenue. This article breaks d...